Utilization, safety, and tolerability of Ocrelizumab: year 2 data from the providence Ocrelizumab registryK. Smoot,T. Stuchiner,L. Lucas,C. Chen,E. Lucassen,K. Kresa-Reahl,L. Grote,S. CohanMULTIPLE SCLEROSIS JOURNAL(2019)引用 2|浏览15暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要